# Palvella Therapeutics, Inc.: filings

PVLA · Nasdaq · CIK 1583648 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pvla.md) · [Financials](/companies/pvla/financials.md) · [Filings](/companies/pvla/filings.md) · [Insiders](/companies/pvla/insiders.md)

## Reports and events: 315 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (8-K 213, 4 203, 3 41, 10-Q 38, SC 13G/A 32, CORRESP 20, 424B3 19, CT ORDER 19, SC 13G 18, UPLOAD 16, 144 15, S-8 14, 10-K 13, EFFECT 13, DEF 14A 12, SCHEDULE 13G/A 11, DEFA14A 10, SC 13D/A 10, 424B5 8, 425 8, S-1/A 8, S-3 7, 10-K/A 6, 4/A 6, SCHEDULE 13G 6, 10-Q/A 5, S-4/A 5, ARS 4, D 4, S-1 4, 8-K/A 3, POS AM 3, S-3/A 2, SC 13D 2, SEC STAFF LETTER 2, 144/A 1, 3/A 1, 424B4 1, 8-A12B 1, CERTNAS 1, S-4 1, SCHEDULE 13D 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-28 | 07:30 ET | [8-K](/filings/0001193125-26-435113.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-435113 |
| 2026-08-04 | 07:51 ET | [10-Q](/filings/0001193125-26-331574.md) | Quarterly report, period 2026-06-30 | 0001193125-26-331574 |
| 2026-08-04 | 07:30 ET | [8-K](/filings/0001193125-26-331556.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-331556 |
| 2026-07-14 | 16:48 ET | [8-K](/filings/0001193125-26-303307.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-303307 |
| 2026-06-30 | 07:36 ET | [8-K](/filings/0001104659-26-079087.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-079087 |
| 2026-06-16 | 08:30 ET | [8-K](/filings/0001104659-26-074338.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-074338 |
| 2026-05-20 | 16:35 ET | [8-K](/filings/0001193125-26-232717.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-232717 |
| 2026-05-15 | 07:30 ET | [8-K](/filings/0001193125-26-225317.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-225317 |
| 2026-05-13 | 07:30 ET | [8-K](/filings/0001193125-26-220607.md) | 8.01 Other events | 0001193125-26-220607 |
| 2026-05-07 | 09:09 ET | [8-K](/filings/0001193125-26-210605.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-210605 |
| 2026-05-07 | 08:30 ET | [10-Q](/filings/0001193125-26-210463.md) | Quarterly report, period 2026-03-31 | 0001193125-26-210463 |
| 2026-04-30 | 16:05 ET | [DEF 14A](/filings/0001104659-26-052875.md) | Proxy statement, period 2026-06-10 | 0001104659-26-052875 |
| 2026-04-13 | 07:30 ET | [8-K](/filings/0001193125-26-151979.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-151979 |
| 2026-04-07 | 07:30 ET | [8-K](/filings/0001193125-26-144540.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-144540 |
| 2026-03-31 | 08:30 ET | [10-K](/filings/0001193125-26-133372.md) | Annual report, period 2025-12-31 | 0001193125-26-133372 |
| 2026-03-31 | 08:00 ET | [8-K](/filings/0001193125-26-133332.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-133332 |
| 2026-02-26 | 17:31 ET | [8-K](/filings/0001104659-26-020667.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-020667 |
| 2026-02-24 | 16:23 ET | [8-K](/filings/0001104659-26-019143.md) | 2.02 Results of operations | 0001104659-26-019143 |
| 2026-02-24 | 07:55 ET | [8-K](/filings/0001193125-26-065308.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-065308 |
| 2026-02-24 | 06:30 ET | [8-K](/filings/0001193125-26-065159.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-065159 |
| 2026-01-29 | 16:08 ET | [8-K](/filings/0001193125-26-029341.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-029341 |
| 2026-01-12 | 07:00 ET | [8-K](/filings/0001193125-26-009724.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-009724 |
| 2025-12-15 | 06:05 ET | [8-K](/filings/0001104659-25-120789.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-120789 |
| 2025-11-12 | 08:33 ET | [10-Q](/filings/0001193125-25-276119.md) | Quarterly report, period 2025-09-30 | 0001193125-25-276119 |
| 2025-11-10 | 16:30 ET | [8-K](/filings/0001193125-25-274378.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-274378 |
| 2025-11-05 | 06:05 ET | [8-K](/filings/0001104659-25-106591.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-106591 |
| 2025-09-24 | 06:01 ET | [8-K](/filings/0001104659-25-092681.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-092681 |
| 2025-09-03 | 07:31 ET | [8-K](/filings/0001104659-25-086685.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-086685 |
| 2025-08-14 | 08:00 ET | [10-Q](/filings/0000950170-25-108438.md) | Quarterly report, period 2025-06-30 | 0000950170-25-108438 |
| 2025-08-14 | 07:30 ET | [8-K](/filings/0000950170-25-108422.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-108422 |
| 2025-06-11 | 16:05 ET | [8-K](/filings/0001104659-25-058532.md) | 5.07 Shareholder vote results | 0001104659-25-058532 |
| 2025-05-15 | 07:45 ET | [10-Q](/filings/0000950170-25-071998.md) | Quarterly report, period 2025-03-31 | 0000950170-25-071998 |
| 2025-05-15 | 07:31 ET | [8-K](/filings/0000950170-25-071988.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-071988 |
| 2025-04-30 | 16:05 ET | [DEF 14A](/filings/0001104659-25-042493.md) | Proxy statement, period 2025-06-10 | 0001104659-25-042493 |
| 2025-03-31 | 07:51 ET | [10-K](/filings/0000950170-25-047212.md) | Annual report, period 2024-12-31 | 0000950170-25-047212 |
| 2025-03-31 | 07:32 ET | [8-K](/filings/0000950170-25-047206.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-047206 |
| 2025-03-04 | 08:00 ET | [8-K](/filings/0001437749-25-006013.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-25-006013 |
| 2025-01-14 | 06:22 ET | [S-1/A](/filings/0001437749-25-001017.md) | Registration statement, amended | 0001437749-25-001017 |
| 2025-01-13 | 07:00 ET | [8-K](/filings/0001437749-25-000924.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-25-000924 |
| 2024-12-31 | 06:04 ET | [S-1](/filings/0001437749-24-038553.md) | Registration statement | 0001437749-24-038553 |
| 2024-12-20 | 17:32 ET | [SCHEDULE 13D](/filings/0001437749-24-038167.md) | Ownership report, active investor | 0001437749-24-038167 |
| 2024-12-16 | 21:53 ET | [8-K](/filings/0001437749-24-037515.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.05 Item not in the standard list; 5.06 Item not in the standard list; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-037515 |
| 2024-12-12 | 16:15 ET | [8-K](/filings/0001437749-24-037350.md) | 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-037350 |
| 2024-12-03 | 08:30 ET | [8-K](/filings/0001437749-24-036506.md) | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-036506 |
| 2024-11-13 | 16:02 ET | [10-Q](/filings/0001437749-24-034891.md) | Quarterly report, period 2024-09-30 | 0001437749-24-034891 |
| 2024-11-06 | 17:01 ET | [DEF 14A](/filings/0001437749-24-033669.md) | Proxy statement, period 2024-12-02 | 0001437749-24-033669 |
| 2024-10-03 | 08:00 ET | [8-K](/filings/0001437749-24-030559.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-030559 |
| 2024-08-14 | 16:01 ET | [10-Q](/filings/0001437749-24-026778.md) | Quarterly report, period 2024-06-30 | 0001437749-24-026778 |
| 2024-08-08 | 16:17 ET | [8-K](/filings/0001437749-24-025565.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001437749-24-025565 |
| 2024-07-24 | 06:40 ET | [8-K](/filings/0001437749-24-023301.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-023301 |

Page 1 of 7. [Older](/companies/pvla/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 28, 2026, 07:31 ET. No prices; not investment advice.